Gastrointestinal Trials
| IMbrave050 | A phase III, multicentre, randomized, Open-label study of atezolizumab (anti-pd-l1 antibody) plus bevacizumab Versus active surveillance as adjuvant Therapy in patients with hepatocellular Carcinoma at high risk of recurrence after surgical resection or ablation. |